Chad Cowan - Oct 1, 2024 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Role: Chief Scientific Officer
Signature: /s/ Douglas Carr, Attorney-in-Fact
Stock symbol: IPSC
Transactions as of: Oct 1, 2024
Transactions value $: $0
Form type: 4
Date filed: 10/3/2024, 06:04 PM

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IPSC	Common Stock	Award	$0	+74.4K	+54.52%	$0.00	211K	Oct 1, 2024	Direct	F1
holding	IPSC	Common Stock						10.7K	Oct 1, 2024	By Trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IPSC	Stock Option (right to buy)	Award	$0	+446K		$0.00	446K	Oct 1, 2024	Common Stock	446K	$1.65	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutics, Inc.'s (the "Company's") common stock. The RSUs vest 25% on October 1, 2025, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.
F2	Shares held by the Cowan Investment Nominee Trust. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
F3	The option vests 25% on October 1, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.